WallStSmart

Merck & Company Inc (MRK)vsOscar Health Inc (OSCR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 335% more annual revenue ($66.57B vs $15.32B). MRK leads profitability with a 4.8% profit margin vs 3.6%. OSCR trades at a lower P/E of 25.4x. OSCR earns a higher WallStSmart Score of 66/100 (B-).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

OSCR

Strong Buy

66

out of 100

Grade: B-

Growth: 10.0Profit: 4.5Value: 5.3Quality: 5.0
Piotroski: 3/9Altman Z: 0.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Intrinsic value data unavailable for OSCR.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

OSCR4 strengths · Avg: 9.3/10
Revenue GrowthGrowth
70.4%10/10

Revenue surging 70.4% year-over-year

EPS GrowthGrowth
125.6%10/10

Earnings expanding 125.6% YoY

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$2.04B8/10

Generating 2.0B in free cash flow

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

OSCR4 concerns · Avg: 3.0/10
P/E RatioValuation
25.4x4/10

Moderate valuation

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-2.4%2/10

ROE of -2.4% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : OSCR

The strongest argument for OSCR centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 70.4% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : OSCR

The primary concerns for OSCR are P/E Ratio, Profit Margin, Piotroski F-Score. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

MRK profiles as a value stock while OSCR is a hypergrowth play — different risk/reward profiles.

OSCR carries more volatility with a beta of 2.37 — expect wider price swings.

OSCR is growing revenue faster at 70.4% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

OSCR scores higher overall (66/100 vs 36/100) and 70.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Oscar Health Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Oscar Health, Inc. offers health insurance products and services to individuals, families, and businesses in the United States. The company is headquartered in New York, New York.

Visit Website →

Want to dig deeper into these stocks?